I've always claimed that the share price won't begin to rise until Bioasis accomplishes some stuff that makes the news in the biotech and financial media. (Making it in popular media would be even bigger, but that would require really substantial clinical accomplishment in such as areas as brain tumours, Alzheimer's, and such.)
This Fierce Pharma
article about J&J and Bioasis is the beginning of that. The financial part isn't known and as a result the agreement didn't make news in the financial media, but Fierce Pharma (not Fierce Biotech) saw fit to report it.
And that's how it starts...
jd